[HTML][HTML] Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort …
CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo… - BMC cancer, 2021 - Springer
Background Afatinib is one of the standard treatments for patients with epidermal growth
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the
use of afatinib in patients with poor performance status (PS≥ 2) are limited. This study
aimed to retrospectively review the clinical outcomes and safety of afatinib treatment in
EGFR-mutation-positive (EGFRm+) NSCLC patients with PS≥ 2. Methods The data for 62
patients who were treated at Linkou Chang Gung Memorial Hospital from January 2010 to …
factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the
use of afatinib in patients with poor performance status (PS≥ 2) are limited. This study
aimed to retrospectively review the clinical outcomes and safety of afatinib treatment in
EGFR-mutation-positive (EGFRm+) NSCLC patients with PS≥ 2. Methods The data for 62
patients who were treated at Linkou Chang Gung Memorial Hospital from January 2010 to …
Background
Afatinib is one of the standard treatments for patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). However, data on the use of afatinib in patients with poor performance status (PS ≥ 2) are limited. This study aimed to retrospectively review the clinical outcomes and safety of afatinib treatment in EGFR-mutation-positive (EGFRm+) NSCLC patients with PS ≥ 2.
Methods
The data for 62 patients who were treated at Linkou Chang Gung Memorial Hospital from January 2010 to August 2019 were retrospectively reviewed. Patients’ clinicopathological features were obtained, and univariate and multivariate analyses were performed to identify possible prognostic factors. Data on adverse events were collected to evaluate general tolerance for afatinib therapy.
Results
Until February 2020, the objective response rate, disease control rate, median progression-free survival (PFS), and overall survival (OS) were 58.1% (36/62), 69.4% (43/62), 8.8 months, and 12.9 months, respectively. The absence of liver metastasis (PFS: p = 0.044; OS: p = 0.061) and good disease control (p < 0.001 for PFS and OS) were independent favorable prognostic factors for PFS and OS. Bone metastasis (p = 0.036) and dose modification (reduction/interruption, p = 0.021) were predictors of disease control.
Conclusion
Afatinib demonstrated acceptable efficacy and safety in the current cohort. This study provided evidence to support the use of afatinib as a first-line treatment in EGFRm+ NSCLC patients with poor PS.
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果